Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
CUE Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Cue Biopharma, Inc.NASDAQ: CUE
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to -94.3%
Operating margin was -94.3% in Q1 FY2026, up 2827.1 pp from a year earlier. On a trailing-twelve-month basis it was -59.8%, up 454.9 pp year over year. Over 3 fiscal years it widened by 4178.5 pp.
Context
- Operating margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 2 analysts of -528.7% for the fiscal year ending Dec 2026, down from -96.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -94.3%-103.2 pp QoQ
- Last fiscal yearDec 2025
- -96.6%+350.3 pp YoY
- LTMMar 2026
- -59.8%+454.9 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -96.6%
- Year-over-year change
- +350.3pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -96.6% | +350.3pp |
| FY2024 | 2024-12-31 | -446.9% | +503.0pp |
| FY2023 | 2023-12-31 | -949.9% | +3325.2pp |
| FY2022 | 2022-12-31 | -4275.1% | -3982.5pp |
| FY2021 | 2021-12-31 | -292.6% | — |
Operating Margin vs competitors
How CUE compares with its peers on the latest reported figures
- CUE's LTM Mar 2026 operating margin of -59.8% is the 2nd highest of the 5 companies compared; the peer median is -831.0%.
- Its year-over-year change of +454.9 pp is the lowest of 4, against a peer median of +16883.6 pp.
- Over three fiscal years its change of +4178.5 pp compares with a peer median of +2560.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | -13.8% | +2082.7 pp | +2560.4 pp | |
| LTM Mar 2026 | -59.8% | +454.9 pp | +4178.5 pp | |
| LTM Mar 2026 | -749.7% | — | — | |
| LTM Mar 2026 | -912.4% | +16883.6 pp | — | |
| LTM Mar 2026 | -18182.8% | +26748.2 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding CUE) | -831.0% | +16883.6 pp | +2560.4 pp | |
Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.94M | 1.25M | 5.49M | 9.29M | 27.47M |
| Cost of Revenue | (1.78M) | 0 | 38.1M | 0 | 0 |
| Gross Profit | 16.72M | 1.25M | (32.61M) | 9.29M | 27.47M |
| Gross Margin | 111.9% | 100.0% | -593.9% | 100.0% | 100.0% |
| Research & Development | 41.35M | 38.58M | 40.8M | 36.3M | 37.74M |
| Selling, General & Admin | 17.31M | 16.17M | 16.68M | 14.59M | 16.24M |
| Operating Expenses | 60.43M | 54.47M | 19.54M | 50.79M | 53.99M |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 3.48M |
| EBITDA | (45.44M) | (50.49M) | (46.05M) | (37.53M) | (22.27M) |
| EBITDA Margin | -304.1% | -4055.5% | -838.8% | -404.1% | -81.1% |
| Operating Income | (43.71M) | (53.23M) | (52.15M) | (41.5M) | (26.52M) |
| Operating Margin | -292.6% | -4275.1% | -949.9% | -446.9% | -96.6% |
| Interest Income | 45.9K | 928.24K | 2.66M | 1.62M | 807K |
| Interest Expense | 0 | 713.82K | 1.25M | 796K | 357K |
| Other Income / Expenses | 45.9K | 215K | 1.42M | 826K | 419K |
| Income Before Tax | (43.67M) | (53.01M) | (50.73M) | (40.67M) | (26.1M) |
| Pre-Tax Margin | -292.3% | -4257.8% | -924.1% | -438.0% | -95.0% |
| Income Tax Expense | 495K | 0 | 0 | 0 | 500K |
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Net Margin | -295.6% | -4257.8% | -924.1% | -438.0% | -96.9% |
| EPS (Basic) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| EPS (Diluted) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| Weighted Avg Shares | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
| Weighted Avg Shares (Diluted) | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.